Anaplastic Lymphoma Kinase Non-Small Cell Lung Cancer Epidemiology Forecast 2026-2035

Anaplastic lymphoma kinase non-small cell lung cancer is a molecular subtype of lung cancer characterized by ALK gene rearrangements. According to Yuting Ji, et al., 2025, estimates, approximately 2.48 million new lung cancer cases and 1.82 million deaths occurred globally in 2022, making lung cancer the most common cancer and the leading cause of cancer mortality worldwide. According to the anaplastic lymphoma kinase non-small cell lung cancer epidemiology forecast, expanding biomarker testing, a deepening ALK inhibitor pipeline, and the adjuvant alectinib approval are collectively expected to grow the diagnosed and treated patient pool across the 8 major markets in the forecast period.

Anaplastic Lymphoma Kinase Non-Small Cell Lung Cancer Epidemiology Forecast Report Coverage

The analyst's “Anaplastic Lymphoma Kinase Non-Small Cell Lung Cancer Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of anaplastic lymphoma kinase non-small cell lung cancer. It projects the future incidence and prevalence rates of anaplastic lymphoma kinase non-small cell lung cancer cases across various populations. The study covers age, gender, and type as major determinants of the anaplastic lymphoma kinase non-small cell lung cancer population. The report highlights patterns in the prevalence of anaplastic lymphoma kinase non-small cell lung cancer over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of anaplastic lymphoma kinase non-small cell lung cancer in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Anaplastic Lymphoma Kinase Non-Small Cell Lung Cancer Understanding: Disease Overview

Anaplastic lymphoma kinase non-small cell lung cancer (ALK+ NSCLC) is a molecularly defined subtype of lung cancer driven by rearrangements in the ALK gene, most commonly forming the EML4-ALK fusion oncogene. These fusion trigger uncontrolled cellular proliferation through constitutive activation of downstream signaling pathways. ALK+ NSCLC predominantly affects younger, never-smoking individuals and presents most frequently as lung adenocarcinoma. Patients are typically diagnosed at advanced stages, often with brain metastases. The discovery of ALK as a therapeutic target has transformed patient outcomes, enabling highly effective, precision-targeted treatment with ALK tyrosine kinase inhibitors.

Anaplastic Lymphoma Kinase Non-Small Cell Lung Cancer Epidemiology Perspective

The anaplastic lymphoma kinase non-small cell lung cancer epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The analyst provides both current and predicted trends for the anaplastic lymphoma kinase non-small cell lung cancer epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for anaplastic lymphoma kinase non-small cell lung cancer and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Jessica J. Lin et al., 2024, anaplastic lymphoma kinase (ALK) gene rearrangements occur in approximately 3-5% of all non-small cell lung cancer cases worldwide, highlighting a relatively low but clinically significant global prevalence within a biomarker-defined subset of lung cancer patients.
• As per Hayat Bazzi et al., 2025, the median age at diagnosis for ALK-positive non-small cell lung cancer is around 52 years, indicating a younger patient population compared to typical lung cancer cohorts, with diagnosis timelines influenced by age and symptom burden.
• According to Peiyao Wang et al., 2024, gender distribution shows a higher prevalence among females, accounting for approximately 57.9% of cases, suggesting a notable gender difference, alongside a predominance of never-smokers and adenocarcinoma histology in this patient group.
• As per Grace Chazan et al., 2026, mortality outcomes have improved significantly with targeted therapies, with median overall survival reaching 90.8 months, reflecting advances in treatment but also indicating ongoing mortality risks associated with advanced-stage presentation and disease progression.
• According to Jessica J. Lin et al., 2024, incidence rates of ALK-positive non-small cell lung cancer remain stable within the 3-5% range, with increasing identification driven by widespread molecular testing and precision oncology approaches enhancing detection and targeted treatment initiation.

Country-wise Anaplastic Lymphoma Kinase Non-Small Cell Lung Cancer Epidemiology

The anaplastic lymphoma kinase non-small cell lung cancer epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

ALK-positive NSCLC accounts for 4% to 5% of all NSCLC cases globally (PMC). The United States holds the largest diagnosed share within the 8MM, supported by approximately 204,800 new NSCLC cases in 2024 (ACS) and ALK testing rates reaching 73% by 2019 (PubMed). The April 2024 adjuvant alectinib approval is expected to expand testing into earlier stages (NCI). In Europe, ESMO guidelines mandate reflex ALK testing for advanced NSCLC, with Germany carrying the highest EU4 burden. The UK benefits from NHS Genomics England and the National Lung Cancer Audit. Japan has a well-developed ALK testing infrastructure, anchored by the J-ALEX trial and domestically developed alectinib. India faces a growing but underdiagnosed burden due to uneven NGS access outside urban academic centers.

Anaplastic Lymphoma Kinase Non-Small Cell Lung Cancer: Treatment Overview

ALK-positive NSCLC is treated primarily with ALK tyrosine kinase inhibitors (TKIs), which are oral targeted therapies that block the abnormal ALK fusion protein driving tumor growth. Treatment has evolved across three generations of TKIs. First-generation crizotinib was the pioneering therapy, followed by more potent second-generation agents, alectinib, brigatinib, and ceritinib, which demonstrated superior efficacy and better central nervous system penetration. Third-generation lorlatinib addresses resistance mutations that develop after earlier-line treatment. Alectinib is currently the most widely adopted first-line standard of care globally. Despite impressive response rates and prolonged survival, resistance inevitably develops, making sequential therapy and ongoing molecular monitoring essential components of long-term disease management.

Key Questions Answered

• What are the key findings of anaplastic lymphoma kinase non-small cell lung cancer epidemiology in the 8 major markets?
• What will be the total number of patients with anaplastic lymphoma kinase non-small cell lung cancer across the 8 major markets during the forecast period?
• What was the country-wise anaplastic lymphoma kinase non-small cell lung cancer epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of anaplastic lymphoma kinase non-small cell lung cancer patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of anaplastic lymphoma kinase non-small cell lung cancer during the forecast period of 2026-2035?
• What are the currently available treatments for anaplastic lymphoma kinase non-small cell lung cancer?
• What are the disease risks, signs, symptoms, and unmet needs of anaplastic lymphoma kinase non-small cell lung cancer?

Scope of the Anaplastic Lymphoma Kinase Non-Small Cell Lung Cancer Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of anaplastic lymphoma kinase non-small cell lung cancer based on several factors.
• Anaplastic Lymphoma Kinase Non-Small Cell Lung Cancer Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The anaplastic lymphoma kinase non-small cell lung cancer report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.